Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques

Vaccine

Volumn 26, Issue 40, 2008, Pages 5210-5215

  Yan, Jian ^a   Harris, Kristina ^a   Khan, Amir S ^b   Draghia Akli, Ruxandra ^b   Sewell, Duane ^c   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VGX Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Consensus; DNA vaccine; E6 and E7 protein; HPV18

Indexed keywords

DNA VACCINE; PROTEIN E6; PROTEIN E7; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, CELLULAR; MACACA MULATTA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 50849116106     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.069     Document Type: Article

References (38)

1. Franceschi S., Rajkumar T., Vaccarella S., Gajalakshmi V., Sharmila A., Snijders P.J., et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer 107 (2003) 127-133
2. de Villiers E.M. Taxonomic classification of papillomaviruses. Papillomavirus Rep 12 (2001) 57-63
3. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
4. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
5. Hildesheim A., Hadjimichael O., Schwartz P.E., Wheeler C.M., Barnes W., Lowell D.M., et al. Rish factors for rapid-onset cervical cancer. Am J Obstet Gynecol 180 (1999) 517-577
6. Munger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 89 (2002) 213-228
7. Eiben G.L., Velders M.P., and Kast W.M. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res 86 (2002) 113-148
8. Peng S., Trimble C., He L., Tsai Y.C., Lin C.T., Boyd D.A., et al. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther 13 (2006) 67-77
9. Lin C.T., Tsai Y.C., He L., Calizo R., Chou H.H., Chang T.C., et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 13 (2006) 481-488
10. Wu T.C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H., and Hedrick L. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci USA 92 (1995) 11671-11675
11. Ji H., Wang T.L., Chen C.H., Pai S.I., Hung C.F., Lin K.Y., et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10 (1999) 2727-2740
12. Chen C.H., Wang T.L., Hung C.F., Pardoll D.M., and Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 18 (2000) 2015-2022
13. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 10 (1999) 759-768
14. Nichols W.W., Ledwith B.J., Manam S.V., and Triolo P.J. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772 (1995) 30-39
15. Chattergoon M., Boyer J., and Weiner D.B. Genetic immunization: a new era in vaccines and immune therapies. FASEB J 11 (1997) 753-763
16. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 (1998) 1497-1503
17. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 gag protein. J Virol 75 (2001) 10991-11001
18. Muthumani K., Zhang D., Dayes N.S., Hwang D.S., Calarota S.A., Choo A.Y., et al. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 314 (2003) 134-146
19. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 (1997) 4892-4903
20. Yang J.S., Kim J.J., Hwang D.S., Choo A.Y., Dang K., Maguire H., et al. Induction of potent Th1-Type immune responses from a novel DNA vaccine for West Nile Virus New York Isolate (WNV-NY1999). J Infect Diseases 184 (2001) 809-816
21. Yan J., Yoon H., Kumar K., Ramanathan M.P., Corbitt N., Kutzler M., et al. Enhanced diversity and magnitude of cellular immune responses elicited by a novel engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 411-421
22. Laddy D.J., Yan J., Corbitt N., Kobasa D., Kobinger G.P., and Weiner D. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25 (2007) 2984-2989
23. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., and Weiner D. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26 (2008) 440-448
24. Luckay A., Sidhu M., Kjeken R., Megati S., Chong S., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in Rhesus macaques. J Virol 81 (2007) 5257-5269
25. Rolland M., Jensen M.A., Nickle D.C., Yan J., Learn G.H., Heath L., et al. Reconstruction and function of ancestral central-of-tree (COT) Human Immunodeficiency Virus Type 1 proteins. J Virol 81 (2007) 8507-8514
26. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B.J., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 79 (2005) 1154-1163
27. Boyer J., Robinson T., Kutzler M., Parkinson R., Calarota S.A., Sidhu M., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Pramatol 34 (2005) 262-270
28. Pim D., Storey A., Thomas M., Massimi P., and Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9 (1994) 1869-1876
29. Crook T., Tidy J.A., and Vousden K. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67 (1991) 547-556
30. Boursnell M.E., Rutherford E., Hickling J.K., Rollinson E.A., Munro A.J., Rolley N., et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14 (1996) 1485-1494
31. McCarthy C., Youde S.J., and Man S. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. Int J Cancer 118 (2006) 2514-2521
32. Petry K.U., Scheffel D., Bode U., Gabrysiak T., Kochel H., Kupsch E., et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57 (1994) 836-840
33. Lamikanra A., Pan Z.K., Isaacs S.N., Wu T.C., and Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 75 (2001) 9654-9664
34. Cheng W.F., Hung C.F., Pai S.I., Hsu K.F., He L., Ling M., et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 9 (2002) 675-687
35. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1 (1995) 1297-1302
36. Van Herck K., Van Damme P., Lievens M., and Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 72 (2004) 194-196
37. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
38. Chan S.Y., Delius H., Halpern A.L., and Bernard H.U. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 69 (1995) 3074-3083